Health Condition 1: null- Gaucher Disease, Type 1
Conditions
Interventions
Intervention1: Biological: Velaglucerase Alfa: Infusion: Every other week
Control Intervention1: None: None
Sponsors
Shire Human Genetic Therapies Inc
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1. The patient has completed study TKT032 or TKT034, or study HGT-GCB-039. 2. Female patients of child-bearing potential must agree to use a medically acceptable method of contraception at all times during the study and must have negative results to a pregnancy test performed at the time of enrollment and as required throughout their participation in the study. 3. Male patients must agree to use a medically acceptable method of contraception at all times during the study and report a partner's pregnancy to the investigator. 4. The patient, the patient's parent(s) or legal guardian(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). 5. The patient must be sufficiently cooperative to participate in this clinical study as judged by the Investigator
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1. The patient has received treatment with any non-Gaucher disease-related investigational drug or device within the 30 days prior to study entry; such use during the study is not permitted. 2. The patient is pregnant or lactating. 3. The patient, patients parent(s), or patients legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study. 4. The patient has a significant comorbidity(ies) that might affect study data or confound the study results (e.g., malignancies, primary biliary cirrhosis, autoimmune liver disease, etc.). 5. The patient is unable to comply with the protocol, e.g., has a clinically relevant medical condition making implementation of the protocol difficult, has an uncooperative attitude, is unable to return for safety evaluations, or is otherwise unlikely to complete the study, as determined by the Investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of safety assessmentsTimepoint: Duration of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| The evaluation of hematological parameters and organomegalyTimepoint: Duration of the Study | — |
Countries
India
Contacts
Public ContactMr Mandar Vaidya
Outcome results
None listed